SCPH SCPharmaceuticals Inc

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals’ management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 9, 2022, to discuss third quarter financial results and provide a business update.

Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13732796. The live webcast and replay of the conference call can be accessed under “News & Events” in the Investor Relations section of the Company’s website, .

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit .

Katherine Taudvin

scPharmaceuticals Inc., 781-301-6706

Investors:

Hans Vitzthum

LifeSci Advisors, 617-430-7578





EN
26/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Reve...

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch